International Isotopes Inc.

OTCPK:INIS Stock Report

Market Cap: US$19.2m

International Isotopes Past Earnings Performance

Past criteria checks 0/6

International Isotopes has been growing earnings at an average annual rate of 14.6%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 5.2% per year.

Key information

14.6%

Earnings growth rate

18.2%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate5.2%
Return on equity-21.5%
Net Margin-7.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How International Isotopes makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:INIS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2312-181
30 Sep 2312-170
30 Jun 2312-171
31 Mar 2311-170
31 Dec 2211071
30 Sep 2210071
30 Jun 2210170
31 Mar 2210160
31 Dec 2110-160
30 Sep 219160
30 Jun 2110260
31 Mar 219260
31 Dec 209260
30 Sep 209050
30 Jun 209-150
31 Mar 209-250
31 Dec 199-250
30 Sep 199-150
30 Jun 1910-250
31 Mar 1910-150
31 Dec 1810-150
30 Sep 1810-140
30 Jun 189-350
31 Mar 188-350
31 Dec 177-450
30 Sep 177-350
30 Jun 177-240
31 Mar 177-240
31 Dec 167-241
30 Sep 167-241
30 Jun 167-241
31 Mar 167-231
31 Dec 157-231
30 Sep 157-231
30 Jun 157-130
31 Mar 158-130
31 Dec 148-230
30 Sep 147-241
30 Jun 147-240
31 Mar 147-241
31 Dec 137-241
30 Sep 137-241
30 Jun 137-241

Quality Earnings: INIS is currently unprofitable.

Growing Profit Margin: INIS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INIS is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare INIS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INIS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).


Return on Equity

High ROE: INIS has a negative Return on Equity (-21.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.